Attention impairment induced by PCP is also reduced in rats by pretreatment with L-NOARG.[26] The selective iNOS inhibitors AG and epigallocatechin gallate reduced PCP-induced hyperkinesia and reversed dizocilpine (MK-801-induced) psychotomimetic symptoms in rats, and both AG and epigallocatechin gallate normalized MK-801-stimulated extracellular glutamate levels in the medial prefrontal cortex.[27] This suggests that modulation of NMDA receptors with NOS inhibitors may be a target for the treatment of schizophrenia cognitive disorders. The gene discussed is NOS1; the disease is schizophrenia.